| Literature DB >> 33664247 |
Hope A Tanudisastro1, Katherine Holman2,3, Gladys Ho2,3,4, Elizabeth Farnsworth2,3, Katrina Fisk2, Thet Gayagay2, Emma Hackett2, Gemma Jenkins2, Rahul Krishnaraj2, Tiffany Lai2, Karen Wong2, Chirag Patel3,5, Amali Mallawaarachchi3,6,7, Andrew J Mallett3,8,9, Bruce Bennetts2,3,4, Stephen I Alexander10,11,12, Hugh J McCarthy13,14,15.
Abstract
Genetic testing in nephrology clinical practice has moved rapidly from a rare specialized test to routine practice both in pediatric and adult nephrology. However, clear information pertaining to the likely outcome of testing is still missing. Here we describe the experience of the accredited Australia and New Zealand Renal Gene Panels clinical service, reporting on sequencing for 552 individuals from 542 families with suspected kidney disease in Australia and New Zealand. An increasing number of referrals have been processed since service inception with an overall diagnostic rate of 35%. The likelihood of identifying a causative variant varies according to both age at referral and gene panel. Although results from high throughput genetic testing have been primarily for diagnostic purposes, they will increasingly play an important role in directing treatment, genetic counseling, and family planning.Entities:
Year: 2021 PMID: 33664247 PMCID: PMC7933190 DOI: 10.1038/s41525-021-00184-x
Source DB: PubMed Journal: NPJ Genom Med ISSN: 2056-7944 Impact factor: 8.617